- Home
- BRNS vs SCLX Comparison
BRNS vs SCLX Comparison
Compare BRNS & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- SCLX
- Stock Information
- Founded
- BRNS 2016
- SCLX 2011
- Country
- BRNS United Kingdom
- SCLX United States
- Employees
- BRNS N/A
- SCLX N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- SCLX Health Care
- Exchange
- BRNS Nasdaq
- SCLX Nasdaq
- Market Cap
- BRNS 42.8M
- SCLX 35.7M
- IPO Year
- BRNS 2021
- SCLX N/A
- Fundamental
- Price
- BRNS $1.44
- SCLX $12.94
- Analyst Decision
- BRNS Strong Buy
- SCLX Strong Buy
- Analyst Count
- BRNS 1
- SCLX 3
- Target Price
- BRNS $3.00
- SCLX $367.50
- AVG Volume (30 Days)
- BRNS 3.8M
- SCLX 225.6K
- Earning Date
- BRNS 08-11-2025
- SCLX 08-12-2025
- Dividend Yield
- BRNS N/A
- SCLX N/A
- EPS Growth
- BRNS N/A
- SCLX N/A
- EPS
- BRNS N/A
- SCLX N/A
- Revenue
- BRNS $14,969,000.00
- SCLX $50,710,000.00
- Revenue This Year
- BRNS N/A
- SCLX $68.30
- Revenue Next Year
- BRNS N/A
- SCLX $124.48
- P/E Ratio
- BRNS N/A
- SCLX N/A
- Revenue Growth
- BRNS 4381.74
- SCLX 7.79
- 52 Week Low
- BRNS $0.64
- SCLX $3.60
- 52 Week High
- BRNS $2.92
- SCLX $57.75
- Technical
- Relative Strength Index (RSI)
- BRNS 53.79
- SCLX 66.20
- Support Level
- BRNS $1.44
- SCLX $10.14
- Resistance Level
- BRNS $2.01
- SCLX $17.76
- Average True Range (ATR)
- BRNS 0.39
- SCLX 1.77
- MACD
- BRNS -0.00
- SCLX 0.68
- Stochastic Oscillator
- BRNS 24.49
- SCLX 58.41
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.